Genmab A/S Passing Of Genmab A/S' Annual General Meeting
30 March 2023 - 12:53AM
UK Regulatory
TIDMGEN
Company Announcement
-- At Genmab A/S' Annual General Meeting held today March 29, 2023, the
Annual Report for 2022 was approved
-- Discharge was given to the Board of Directors and the Executive
Management and the year's profit was carried forward
-- The 2022 Compensation Report was approved
-- Six members of the Board of Directors were re-elected
-- PricewaterhouseCoopers was re-elected as auditor of the Company
-- The proposals from the Board of Directors on the Board of Directors'
remuneration for 2023, the proposals on the amended Remuneration Policy
and the proposal to acquire treasury shares were adopted
COPENHAGEN, Denmark; March 29, 2023 --
https://www.globenewswire.com/Tracker?data=GV6fFHnp7DMV71X4OJbVY99Cw21RWtv8S767KsjYTaQvYNcPbA_CMQrtc8iOmGpSvh3nz_fDrTWx2Im-7d7ucw==
Genmab A/S (Nasdaq: GMAB) held its Annual General Meeting, today at
the Copenhagen Marriott Hotel, Copenhagen, Denmark. At the meeting,
Deirdre P. Connelly, Chair of the Board of Directors gave -- on
behalf of the Board of Directors -- a report on the Company's
activities during the past year. Chief Executive Officer Dr. Jan
van de Winkel presented the Company's plans for 2023, and Chief
Financial Officer Mr. Anthony Pagano presented the Annual Report
for 2022 endorsed by the auditors. The report was approved, and
discharge was given to the Board of Directors and the Executive
Management.
It was decided that the year's profit of DKK 5,522 million be
carried forward by transfer to retained earnings, as stated in the
Annual Report.
The 2022 Compensation Report was approved.
Ms. Deirdre P. Connelly, Ms. Pernille Erenbjerg, Mr. Rolf
Hoffmann, Dr. Paolo Paoletti, Dr. Anders Gersel Pedersen and Ms.
Elizabeth O'Farrell were re-elected to the Board of Directors for a
one-year period.
PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab
was re-elected as the Company's auditor.
The General Meeting adopted the proposals from the Board of
Directors, as follows:
-- The proposal to adopt the Board of Directors' remuneration for 2023.
-- The proposals to adopt an amended Remuneration Policy for the Board of
Directors and the Executive Management.
-- The proposal to authorize the Board of Directors to mandate the Company
to acquire treasury shares up to a nominal amount of DKK 500,000.
About Genmab
Genmab is an international biotechnology company with a core
purpose guiding its unstoppable team to strive towards improving
the lives of patients through innovative and differentiated
antibody therapeutics. For more than 20 years, its passionate,
innovative and collaborative team has invented next-generation
antibody technology platforms and leveraged translational research
and data sciences, which has resulted in a proprietary pipeline
including bispecific T-cell engagers, next-generation immune
checkpoint modulators, effector function enhanced antibodies and
antibody-drug conjugates. To help develop and deliver novel
antibody therapies to patients, Genmab has formed 20+ strategic
partnerships with biotechnology and pharmaceutical companies. By
2030, Genmab's vision is to transform the lives of people with
cancer and other serious diseases with Knock-Your-Socks-Off (KYSO)
antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen,
Denmark with locations in Utrecht, the Netherlands, Princeton, New
Jersey, U.S. and Tokyo, Japan. For more information, please visit
Genmab.com
https://www.globenewswire.com/Tracker?data=GV6fFHnp7DMV71X4OJbVY2RsX2jdWj7Z0eSicz51PjSi6234cb9ma535I6MvTgGJ6VRGc0-Ddd42oGES4jIjHQ==
and follow us on Twitter.com/Genmab
https://www.globenewswire.com/Tracker?data=1JFZ_vm4g9KInCiOqUwcmqQktVJaxAjPjsPvwcHvzE0Tk6sZqhrqQPg7NBC2ic5p57bJsRSnql8YJR0slWkaZoan1BOA-6Mru_kdkgzuP_A=
.
Contact:
Marisol Peron, Senior Vice President, Global Communications
& Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
https://www.globenewswire.com/Tracker?data=47DCb-aqdGirhhdMCg4oagB6FOj9HAyLxblwSswC-flCznHMycICZ88catucFfbFyqa1A36Hp9i2YrpKmjFBuA==
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
https://www.globenewswire.com/Tracker?data=I5FvjaIf6FA0W2Oo1V1Uako3UYgJ2km02y2DqLQoXpOcPCa1o9S1cwsHj2vUvuoHASX_uLDH6XLylXPOXzbfWA==
This Company Announcement contains forward looking statements.
The words "believe", "expect", "anticipate", "intend" and "plan"
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab's most recent financial reports, which are
available on
https://www.globenewswire.com/Tracker?data=Rb2feIhCwODwsTf1AkYBKmS3JDjAwf4r3usZ1WLrAWvIR6PzYirXpJKCVyjLdVOcr45zkbqBewlRwlZiXznpYQ==
www.genmab.com and the risk factors included in Genmab's most
recent Annual Report on Form 20-F and other filings with the U.S.
Securities and Exchange Commission (SEC), which are available at
https://www.globenewswire.com/Tracker?data=Rb2feIhCwODwsTf1AkYBKvnT3OVm6XIhXfUHHL5FQucFilHttYQJ5YgGskCzKN3nTmCZrgYp-jJoU5CjiGdzlKFg1ktqjYHhQWxqVQGbjm8=
www.sec.gov. Genmab does not undertake any obligation to update or
revise forward looking statements in this Company Announcement nor
to confirm such statements to reflect subsequent events or
circumstances after the date made or in relation to actual results,
unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks:
Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination
with the Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ; DuoBody
in combination with the DuoBody logo(R) ; HexaBody(R) ; HexaBody in
combination with the HexaBody logo(R) ; DuoHexaBody(R) and
HexElect(R) .
Company Announcement no. 17
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Attachment
-- 290303_CA17_Passing of AGM
https://ml-eu.globenewswire.com/Resource/Download/a70cf8b2-1a7c-4805-bcbb-668a8fab9819
(END) Dow Jones Newswires
March 29, 2023 09:53 ET (13:53 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Genuit (LSE:GEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genuit (LSE:GEN)
Historical Stock Chart
From Apr 2023 to Apr 2024